Author:
Patel Nikunjkumar,Hatley Oliver,Berg Alexander,Romero Klaus,Wisniowska Barbara,Hanna Debra,Hermann David,Polak Sebastian
Publisher
Springer Science and Business Media LLC
Reference71 articles.
1. Piccini JP, Whellan DJ, Berridge BR, Finkle JK, Pettit SD, Stockbridge N, et al. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am Heart J. 2009;158(3):317–26.
2. Redfern W, Ewart L, Hammond T, Bialecki R, Kinter L, Lindgren S, et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist. 2010;114(S1):1081.
3. Laverty HG, Benson C, Cartwright EJ, Cross MJ, Garland C, Hammond T, et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol. 2011;163(4):675–93. https://doi.org/10.1111/j.1476-5381.2011.01255.x .
4. Stockbridge N, Morganroth J, Shah RR, Garnett C. Dealing with global safety issues. Drug Saf. 2013:1–16.
5. Guth BD, Germeyer S, Kolb W, Markert M. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. J Pharmacol Toxicol Methods. 2004;49(3):159–69.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献